Director/PDMR Shareholding

RNS Number : 5565R
AstraZeneca PLC
30 June 2020
 

30 June 2020 15:00 BST

 

 

Transaction by Person Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 29 June 2020, it was notified by Pascal Soriot, Chief Executive Officer, that, on 29 June 2020, Mr Soriot ceased to be beneficially interested in 127,389 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.

 

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Pascal Soriot

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Gift of shares to family members for nil consideration

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

0

127,389

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

e)

 

Date of the transaction

 

 

29 June 2020

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHURUARRKUNOAR

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings